Differentiation of Human Induced Pluripotent Stem Cells to Brain Microvascular Endothelial Cell-Like Cells with a Mature Immune Phenotype
May 19th, 2023
Here, we describe a protocol, the extended endothelial cell culture method (EECM), that allows differentiation of pluripotent stem cells to brain microvascular endothelial cell (BMEC)-like cells. These cells show endothelial cell adhesion molecule expression and are thus a human blood-brain barrier model suitable to study immune cell interactions in vitro.
Overview
This article presents a protocol for differentiating human-induced pluripotent stem cells into brain microvascular endothelial cell-like cells using the extended endothelial cell culture method (EECM). These cells exhibit properties of the blood-brain barrier, making them suitable for studying immune cell interactions in vitro.
Key Study Components
Area of Science
- Neuroscience
- Cell Biology
- Stem Cell Research
Background
- Brain microvascular endothelial cells (BMECs) form the blood-brain barrier.
- Understanding immune cell migration across the blood-brain barrier is crucial for studying neurological diseases.
- Current models for studying these interactions are limited.
- The EECM provides a novel approach for generating BMEC-like cells from pluripotent stem cells.
Purpose of Study
- To develop a reliable method for generating BMEC-like cells from human-induced pluripotent stem cells.
- To create a model for studying immune cell interactions with the blood-brain barrier.
- To investigate intrinsic barrier defects in models derived from multiple sclerosis patients.
Methods Used
- Extended endothelial cell culture method (EECM) for differentiation.
- Flow cytometry for assessing cell purity and characteristics.
- Microscopy to observe cell morphology during culture.
- Cell counting and centrifugation for cell preparation.
Main Results
- EECM successfully differentiates pluripotent stem cells into BMEC-like cells.
- These cells display mature tight junctions and adhesion molecule expression.
- Models derived from MS patients reveal intrinsic barrier defects.
- The method can be applied to other diseases involving the blood-brain barrier.
Conclusions
- The EECM provides a valuable tool for studying the blood-brain barrier.
- This approach may help identify molecular pathways involved in barrier dysfunction.
- Future applications could extend to various neurological conditions.
Frequently Asked Questions
Executive Industry Relevance
Establishing robust in vitro blood-brain barrier (BBB) models using hiPSC-derived brain microvascular endothelial cell-like cells with mature immune phenotypes addresses a critical gap in neuroinflammatory and neurodegenerative disease research. This capability enables mechanistic de-risking and target validation for BBB stabilization strategies, supporting predictive confidence in early discovery and translational pipelines. The EECM protocol facilitates personalized disease modeling and immune cell interaction studies, directly impacting portfolio prioritization for CNS drug development.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables interrogation of BBB-specific molecular pathways implicated in disease pathogenesis.
- Supports functional validation of targets involved in immune cell migration and barrier integrity.
- Facilitates mechanistic de-risking by modeling patient-specific BBB defects.
- Provides predictive confidence for advancing BBB-targeted therapeutic hypotheses.
Screening & Assay Development
- Delivers standardized, reproducible BBB models with mature tight junctions and adhesion molecule expression.
- Enables quantitative assessment of immune cell transmigration and adhesion under controlled conditions.
- Supports assay scalability and platform reuse for compound screening targeting BBB function.
- Prepares validated biological systems for downstream immune interaction studies.
Translational & Preclinical Research
- Aligns in vitro BBB models with disease-relevant immune phenotypes for translational biomarker exploration.
- Enables continuity from discovery through preclinical validation of BBB-targeted interventions.
- Supports risk-adjusted advancement decisions by modeling patient-derived barrier defects.
- Provides a platform for evaluating therapeutic strategies in neuroinflammatory and neurodegenerative contexts.
Pipeline & Workflow Integration
This method integrates into the discovery-to-preclinical continuum by enabling hypothesis testing, target validation, and mechanistic studies of BBB function and immune interactions.
- Discovery Biology: Supports pathway clarification and biological de-risking for BBB-related targets.
- Screening: Provides reproducible, quantitative outputs for immune cell migration and adhesion assays.
- Analytics: Delivers flow cytometry and immunofluorescence readouts for comparative analysis of barrier properties.
- Translational Research: Bridges in vitro findings to preclinical models by recapitulating patient-specific BBB phenotypes.
- Enterprise Reuse: Establishes a reusable hiPSC-derived BBB platform for diverse CNS disease modeling and screening needs.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in BBB-targeted research.
- Operational Value: Standardizes BBB model generation and enables reproducible immune interaction assays.
- Strategic Value: Improves go/no-go decisions and capital efficiency by enabling early de-risking of CNS programs.
- Portfolio Impact: Supports risk-adjusted prioritization and advancement of BBB-focused therapeutic candidates.
Implementation Considerations
- Requires expertise in hiPSC culture, endothelial differentiation, and immune cell assays.
- Needs access to flow cytometry, immunofluorescence, and cell sorting instrumentation.
- Demands cross-team standardization of seeding density and differentiation protocols.
- May require adaptation for different hiPSC clones or disease backgrounds.
- Dependent on careful control of cytokine stimulation and co-culture conditions for reproducibility.
Biopharma FAQs
Chapters in this video
0:04
Introduction
1:33
Magnetic Activated Cell Sorting (MACS) to Purify CD31+ Endothelial Progenitor Cells (EPCs)
5:27
Selective Passage to Purify EECM‐BMEC‐Like Cells and SMLCs
7:07
Results: Immunofluorescence Staining, Flow Cytometry Analysis, and Immune Cell Adhesion
8:29
Conclusion
